At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 180 enrolled
Drug / intervention
HIV vaccine 732461biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose-ranging Study to Compare the Safety and Immunogenicity of a Candidate Human Deficiency Virus (HIV) Vaccine 732461, Adjuvanted or Not, Administered According to a 0, 1 Month Schedule to Healthy Adult HIV Seronegative Volunteers.
In Brief
A Phase 2 clinical trial evaluating HIV vaccine 732461 for AIDS and HIV Infections. Completed, enrolled 180 participants across 1 site.
Detailed Summary
GSK has constructed a new HIV immunogen comprised of conserved parts of the HIV virus (gag, pol and nef). The principal objectives of this study are to evaluate the reactogenicity and safety of this candidate vaccine with or without a GSK proprietary adjuvant system at three different doses and to evaluate the CD4+ T-cell response in terms of proportion of responders to the antigens two weeks after the second vaccination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAIDS, HIV Infections
CountriesBelgium
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2007
Enrollment StartFeb 2007
Primary CompletionJun 2008
TodayJul 2026
First PostedFeb 13, 2007
Enrollment StartFeb 20, 2007
Primary CompletionJun 13, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.4 years ago
Interventions
HIV vaccine 732461biological